Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fuji Yakuhin Files Hyperuricemia Candidate Dotinurad
December 26, 2018
- Fujifilm, MIT Launch Research Project on Oligonucleotide DDS
December 26, 2018
- INCJ Makes Further Investment in NapaJen Pharma
December 26, 2018
- RaQualia’s Tegoprazan Sublicensed to Vietnam’s Vimedimex
December 26, 2018
- Some Drug Makers Stop Distributing 2019 Calendars with Revised JPMA Code of Practice Set to Take Effect in January
December 25, 2018
- Takeda Completes M&A Bridge Re-Financing
December 25, 2018
- Mundipharma Files for Japan Approval of Anesthetic Remimazolam
December 25, 2018
- Kyoto Univ., Sumitomo Dainippon, Sumitomo Chemical Team Up for Research on iPS Cell Production
December 25, 2018
- Xtandi Smashes Primary Goal in Patients with mHSPC in PIII Trial
December 25, 2018
- Daiichi Sankyo Kicks Off 1st Combo Study for Its 2 AML Meds
December 21, 2018
- Fuji Pharma Invests US$50 Million in Alvotech to Boost Biosimilar Business in Japan
December 21, 2018
- ViiV’s HIV Drug Juluca Now Available in Japan
December 21, 2018
- Kowa Reps Continue Heavy GP Pitch for Parmodia in September: Anterio
December 21, 2018
- Taisho to Develop Overseas Biz in Asia and Europe through BMS’s Consumer Unit Buyout
December 21, 2018
- Fujifilm to Set Up New iPS Cell Production Facility in US, Start Operations in FY2019
December 21, 2018
- Life Science Institute Initiates Exploratory Clinical Trial of Muse Cell Product for Epidermolysis Bullosa
December 21, 2018
- Taisho to Acquire Bristol-Myers’s Consumer Health Unit
December 20, 2018
- Chugai’s Satralizumab Wins FDA Breakthrough Therapy Status
December 20, 2018
- ROS1/TRK Inhibitor Entrectinib Filed in Japan: Chugai
December 20, 2018
- Toray Sues Sawai, Fuso over Use Patent for Remitch OD Tablets
December 20, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…